Pathology | BRCA1 adjustment | BRCA2 adjustment | Notes |
Breast | |||
Her2 +ve | −4* | 0 | No other alteration to score on basis of pathology needed |
Lobular | −2 | 0 | Add or subtract ER status |
DCIS only (no invasive cancer) | −1 | 0 | Add or subtract ER status |
LCIS only (no invasive cancer) | −4* | 0 | No other adjustment |
Grade 1 IDC | −2 | 0 | Add or subtract ER status |
Grade 2 IDC | 0 | 0 | Add or subtract ER status |
Grade 3 IDC | +2 | 0 | Add or subtract ER status |
ER +ve | −1 | 0 | Add or subtract grade |
ER −ve | +1 | 0 | Add or subtract grade |
Grade 3 triple −ve | +4* | 0 | No other alteration to score on basis of pathology needed |
Ovary | |||
Epithelial (endometrioid, serous, clear cell, NOS), granulosa cell | 0 no change to score | 0 | No adjustment to ovarian score, ie, 5 points for cancers >59 years for each gene |
Mucinous | No score given for index case or other relative | No score given for index case or other relative | Do not include in scoring at all |
Borderline | No score given for index case or other relative | No score given for index case or other relative | Do not include in scoring at all |
Germ cell tumours except granulosa cell | No score given for index case or other relative | No score given for index case or other relative | Do not include in scoring at all |
*These adjustments are final, and no further adjustment based on other pathological features is necessary.
DCIS, ductal carcinoma in situ; ER, oestrogen receptor; IDC, invasive ductal carcinoma; LCIS, lobular carcinoma in situ; NOS, not otherwise specified.